Ridaforolimus

Type: Product
Name: Ridaforolimus
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely

Following its late 2012 approval by the Food and Drug Administration to treat two rare types of leukemia, Ariad Pharmaceuticals ' ( NASDAQ: ARIA     ) shareholders have experienced the full roller-coaster ride of unwavering success and unfathomable ... [Published Motley Fool Discussion Boards - Apr 04 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 1 reports

Why Now Is The Time To Buy Ariad Pharmaceuticals

SummaryIclusig EMA risk investigation results expected May 2014 provide short term catalysts for traders. Expansion into an additional 16 European countries & Australia + possible Japanese approval expected 2015. Analysts projected Iclusig sales upwards ... [Published Seeking Alpha - Mar 24 2014]
First reported Feb 28 2014 - Updated Feb 28 2014 - 1 reports

DOTW Keeps Tabs As Tax Trimming Fuels Deals

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ... [Published The IN VIVO Blog - Feb 28 2014]
First reported Feb 25 2014 - Updated Feb 25 2014 - 1 reports

Merck Abandons Once-Promising Experimental Cancer Drug to Ariad

Merck & Co. Inc.  ( NYSE:MRK ) has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc.  ( NASDAQ:ARIA ) Merck informed Ariad last week that it was terminating its license agreement ... [Published Wall St. Cheat Sheet - Feb 25 2014]

Quotes

...Ariad has $237.2M in cash as of 31 December 2013 and "anticipates cash used in operations in 2014 to range from $165M to $175M" . Ariad anticipates 'sufficient cash to fund operations until mid-2015'...

More Content

All (5) | News (3) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
3 Reasons an Ariad Pharmaceuticals Buyout Is Un... [Published Motley Fool Discussion Boards - Apr 04 2014]
Why Now Is The Time To Buy Ariad Pharmaceuticals [Published Seeking Alpha - Mar 24 2014]
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
Merck Abandons Once-Promising Experimental Canc... [Published Wall St. Cheat Sheet - Feb 25 2014]
CEO Interview: Harvey Berger, Ariad Pharmaceuti... [Published Pharmaceutical Executive - Aug 01 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ...
Merck Abandons Once-Promising Experimental Canc... [Published Wall St. Cheat Sheet - Feb 25 2014]
Merck & Co. Inc.  ( NYSE:MRK ) has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc.  ( NASDAQ:ARIA ) Merck informed Ariad last week that it was terminating its license agreement ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.